Alefacept

Jump to: navigation, search
Alefacept
Clinical data
Pregnancy
category
  • AU: C
  • US: B (No risk in non-human studies)
Routes of
administration
Intravenous, intramuscular
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability63% (IM)
Elimination half-life~270 hours
Identifiers
CAS Number
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC2306H3594N610O694S26
Molar mass51801.1 g/mol

WikiDoc Resources for Alefacept

Articles

Most recent articles on Alefacept

Most cited articles on Alefacept

Review articles on Alefacept

Articles on Alefacept in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Alefacept

Images of Alefacept

Photos of Alefacept

Podcasts & MP3s on Alefacept

Videos on Alefacept

Evidence Based Medicine

Cochrane Collaboration on Alefacept

Bandolier on Alefacept

TRIP on Alefacept

Clinical Trials

Ongoing Trials on Alefacept at Clinical Trials.gov

Trial results on Alefacept

Clinical Trials on Alefacept at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Alefacept

NICE Guidance on Alefacept

NHS PRODIGY Guidance

FDA on Alefacept

CDC on Alefacept

Books

Books on Alefacept

News

Alefacept in the news

Be alerted to news on Alefacept

News trends on Alefacept

Commentary

Blogs on Alefacept

Definitions

Definitions of Alefacept

Patient Resources / Community

Patient resources on Alefacept

Discussion groups on Alefacept

Patient Handouts on Alefacept

Directions to Hospitals Treating Alefacept

Risk calculators and risk factors for Alefacept

Healthcare Provider Resources

Symptoms of Alefacept

Causes & Risk Factors for Alefacept

Diagnostic studies for Alefacept

Treatment of Alefacept

Continuing Medical Education (CME)

CME Programs on Alefacept

International

Alefacept en Espanol

Alefacept en Francais

Business

Alefacept in the Marketplace

Patents on Alefacept

Experimental / Informatics

List of terms related to Alefacept

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Alefacept is a genetically engineered immunosuppressive drug sold under the brand name Amevive in Canada, the United States, and Australia. It is used to control inflammation in moderate to severe psoriasis with plaque formation, where it interferes with lymphocyte activation.[1]

Mode of Action

The exact mode of action is very complicated, but is has been explored that alefacept inhibits the activation of CD2+, CD4+, and CD8+ T cells which in return stimulate hyperproliferation of keratinocyts resulting in the typical psoriatic symptoms. Therefore, alefacept leads to clinical improvement of moderate to severe psoriasis by blunting these reactions.

Drawbacks

Due to safety issues (immunosuppression, risk of infections, malignancies, and allergies) the European Medicines Agency (EMEA) has so far rejected to approve alefacept.

Indications

Alefacept is indicated for the management of patients with moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. The concomitant use of low-potency topical corticosteroids was permitted during the treatment phase with alefacept and does not seem to pose any additional risks.

The drug was approved based upon studies involving 1,869 patients altogether with plaques covering at least 10% of body surface. Either 7.5 mg IV or 15 mg IM once a week were applied. The long term results (reduction of at least 75% in pretreatment PASI scores) were 14% and 21%, respectively. Additional improvements ensuing after completion of the 12-week treatment phase or after completion of a second alefacept treatment were also seen. Often the remissions were maintained for 7 to 12 months after end of treatment.

Contraindications and Precautions

  • Alefacept reduces CD4+ T cell counts and may worsen the clinical course of HIV infections. It is therefore contraindicated in patients with HIV infections.
  • Pretreatment CD4+ and/or CD8+ cell counts below the accepted lower limit
  • History of systemic malignancy
  • Caution: Patients at high risk to develop a systemic malignancy
  • Known hypersensitivity to alefacept or to any other ingredient of the preparation
  • Caution: There is little experience in geriatric patients (65 years of age or older); so far no differences to the younger age group have been noted.

Pregnancy and Lactation

  • Alefacept has been assigned to Pregnancy Category B in the US and to C in Australia.
  • Lactation : It is not known if the drug is excreted into human milk. Either the drug or breastfeeding should be terminated, taking into account the importance of treatment to the mother.

Pediatric Patients

No clinical experience exists in patients under 18 years of age. The drug should therefore not be used in pediatric patients.

Side effects

  • Lymphopenia : Most common in clinical trials was a significant and dose-related reduction of CD4+ and CD8+ counts in 10 to 59% of patients. However, only 0 to 2% of patients experienced reductions below the accepted lower limit. Consequences of lymphopenia may be infections and/or treatment related malignancies (see below).
  • Malignancies : In clinical studies among 1,869 patients 63 treatment-emerged malignancies in 43 patients were observed. Most of these were nonmelanoma and melanoma skin cancers, other solid tumors, and lymphomas.
  • Infections : In clinical studies 0.9% of patients experienced significant infections compared to 0.2% in the placebo group. Among the infections were serious ones such as sepsis, pneumonia, abscesses, wound infections and toxic shock syndrome.
  • Sensitivity reactions: Urticaria and angioedema were observed. If an anaphylactic reaction should occur symptomatic treatment should be initiated at once.
  • Forming of antibodies to alefacept : About 3% of patients developed low-titer antibodies with unknown importance for the clinical efficiency of the drug. Longterm immune effects have not been well explored.
  • Hepatic Toxicity : Postmarketing reports revealed asymtomatic increases in transaminases (ALT and/or AST), fatty liver degeneration, decompensation of preexisting liver cirrhosis, and acute treatment-related liver failure. It is not known if some or all of these manifestations are attributable to alefacept-therapy, but it is recommended to discontinue therapy as soon as any sign of liver toxicity develops.
  • Different Common Side Effects : side effects such as pharyngitis, cough, dizziness, nausea, pruritus, myalgias, chills, and reactions at injection sites were observed quite frequently.

Interactions

  • Patients currently undergoing immunosuppressive therapy (phototherapy, or concomitant application of other immunosuppressant agents) should not receive alefacept in order to avoid the risks of excessive immunosuppression. Studies concerning the combination with cyclosporine or methotrexate are conducted, but no results have been published so far.
  • Live vaccines : The efficiency of concomitant application of live vaccines has not been fully examined yet. However, the effect of tetanus toxoid was well preserved in clinical trials.

Necessary Laboratory Examinations

  • CD4+ cell counts should be obtained before initiation of therapy and during the 12-week course of therapy in intervals of 2 weeks.
  • It may be desirable to monitor liver function studies (AST and ALT) in patients at high risk to develop liver toxicity (e.g., preexisting hepatitis, or high daily consumption of alcohol).

Dosage Regimes

The standard dosage regime is the weekly application of either 7.5 mg IV or 15 mg IM for a course of 12 weeks. The benefits and risks of repeated courses have not been explored in sufficient detail. Therapy should be conducted under the supervision of a physician experienced in the use of immunosuppressant agents.

Notes

  1. "New drugs". Australian Prescriber. 27 (101): 5. 2004. Retrieved 2006-08-20.

External links

  • Koo J, Bagel J, Sweetser M, Ticho B. "Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study". J Drugs Dermatol. 5 (7): 623–8. PMID 16865867.
  • Krell J (2006). "Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept". J Am Acad Dermatol. 54 (6): 1099–101. PMID 16713481.
  • Parrish C, Sobera J, Robbins C, Cantrell W, Desmond R, Elewski B (2006). "Alefacept in the treatment of psoriatic nail disease: a proof of concept study". J Drugs Dermatol. 5 (4): 339–40. PMID 16673801.
  • AHFS Database online